Carmell Past Earnings Performance
Past criteria checks 0/6
Carmell's earnings have been declining at an average annual rate of -26.6%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 28.5% per year.
Key information
-26.6%
Earnings growth rate
20.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 28.5% |
| Return on equity | n/a |
| Net Margin | -29,675.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Carmell makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -10 | 4 | 0 |
| 30 Jun 24 | 0 | -16 | 3 | 1 |
| 31 Mar 24 | 0 | -18 | 3 | 2 |
| 31 Dec 23 | 0 | -17 | 3 | 2 |
| 30 Sep 23 | 4 | -23 | 8 | 4 |
| 30 Jun 23 | 0 | -17 | 4 | 3 |
| 31 Mar 23 | 0 | -10 | 3 | 2 |
| 31 Dec 22 | 0 | -10 | 3 | 2 |
| 30 Sep 22 | 0 | -7 | 1 | 2 |
Quality Earnings: CTCX is currently unprofitable.
Growing Profit Margin: CTCX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CTCX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CTCX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTCX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CTCX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.